A Phase 2 Open-label Multicenter study to evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in children from 2 years to less than 18 years of age with generalized Myasthenia Gravis (gMG) (THYME)

Principal Investigator

Dr Sithara Ramdas

Contact us

Email: childrensresearch@ouh.nhs.uk

IRAS number

1013092